| Adverse events in cancer genetic testing: medical, ethical, legal, and financial implications KL Brierley, E Blouch, W Cogswell, JP Homer, D Pencarinha, ... The Cancer Journal 18 (4), 303-309, 2012 | 113 | 2012 |
| Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing C Stanislaw, Y Xue, WR Wilcox Cancer biology & medicine 13 (1), 55, 2016 | 70 | 2016 |
| Presymptomatic ALS genetic counseling and testing: experience and recommendations M Benatar, C Stanislaw, E Reyes, S Hussain, A Cooley, MC Fernandez, ... Neurology 86 (24), 2295-2302, 2016 | 62 | 2016 |
| Adverse events in cancer genetic testing: the third case series DC Bonadies, KL Brierley, RE Barnett, MD Baxter, T Donenberg, ... The Cancer Journal 20 (4), 246-253, 2014 | 59 | 2014 |
| Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases M Benatar, J Wuu, C McHutchison, RB Postuma, BF Boeve, R Petersen, ... Brain 145 (1), 27-44, 2022 | 45 | 2022 |
| Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis JH Fanos, S Gronka, J Wuu, C Stanislaw, PM Andersen, M Benatar Genetics in Medicine 13 (4), 342-348, 2011 | 41 | 2011 |
| Validation of version 3.0 of the breast cancer genetics referral screening tool (B-RST™) C Bellcross, A Hermstad, C Tallo, C Stanislaw Genetics in Medicine 21 (1), 181-184, 2019 | 33 | 2019 |
| Validation of the Pedigree Assessment Tool (PAT) in Families with BRCA1 and BRCA2 Mutations P Teller, KF Hoskins, A Zwaagstra, C Stanislaw, R Iyengar, VL Green, ... Annals of Surgical Oncology 17, 240-246, 2010 | 29 | 2010 |
| Prevention and screening in hereditary breast and ovarian cancer SB Zeichner, C Stanislaw, JL Meisel Oncology (Williston Park) 30 (10), 896-904, 2016 | 20 | 2016 |
| Oculodentodigital dysplasia with cerebral white matter abnormalities: an additional case CL Stanislaw, C Narvaez, RG Rogers, CS Woodard Proc Greenwood Genet Center 17, 20-24, 1998 | 13 | 1998 |
| Impact of implementing B-RSTTM to screen for hereditary breast and ovarian cancer on risk perception and genetic counseling uptake among women in an academic safety net hospital K Wernke, C Bellcross, S Gabram, N Ali, C Stanislaw Clinical Breast Cancer 19 (4), e547-e555, 2019 | 8 | 2019 |
| Hereditary Colorectal Cancer Diagnosis by Next‐Generation Sequencing T Wen, F Ehivet, C Stanislaw, R Mao, M Hegde Current Protocols 3 (12), e941, 2023 | 1 | 2023 |
| Pre-Symptomatic Loss Of Cerebral White Matter Integrity In Those At Genetic Risk Of Amyotrophic Lateral Sclerosis (S26. 004) M Turner, N Filippini, V Govind, P Andersen, C Stanislaw, E Reyes, ... Neurology 82 (10_supplement), S26. 004, 2014 | 1 | 2014 |
| Adverse events in cancer genetic testing KL Brierley, E Blouch, W Cogswell, JP Homer, D Pencarinha, ... Handbook of Clinical Cancer Genetics, 57, 2013 | 1 | 2013 |
| Low maternal serum estriol as a marker for steroid sulfatase deficiency CL Stanislaw, RC Rogers, K Stewart, MC Phelan Genetics in Medicine 2 (1), 102-102, 2000 | 1 | 2000 |
| Evaluating the Effectiveness of a Telehealth Cancer Genetics Program: A BRCA Pilot Study E Rose, MW Hardy, R Gates, C Stanislaw, J Meisel, KA Grinzaid Public Health Genomics 25 (5-6), 141-154, 2022 | | 2022 |
| Science Repository C Bellcross, A Hermstad, C Tallo, C Leonard, I Pencea, C Stanislaw | | 2021 |
| Identification and referral of women at risk for BRCA mutations. C Bellcross, A Hermstad, CL Tallo, C Leonard, I Pencea, CL Stanislaw, ... Journal of Clinical Oncology 36 (15_suppl), 1514-1514, 2018 | | 2018 |
| A clinical trial to increase the identification, genetic counseling referral and genetic testing of women at risk for hereditary breast and/or ovarian cancer C Bellcross, C Stanislaw, A Hermstad, C Tallo, C Leonard Journal of the Georgia Public Health Association 7 (1), 67-67, 2017 | | 2017 |
| Models of ALS Disease Onset and Progression: Insights from the Pre-fALS Study (P4. 133) M Benatar, R Carlile, E Reyes, S Hussain, N Garcia, P Andersen, ... Neurology 84 (14_supplement), P4. 133, 2015 | | 2015 |
